Acute lymphoblastic leukemia
What is acute lymphoblastic leukemia?
Acute lymphoblastic leukemia (ALL) starts in blood stem cells and develops quickly. It is the least common of the 4 major types of leukemia in adults.
Risk factors for acute lymphoblastic leukemia (ALL)
Risk factors for acute lymphoblastic leukemia (ALL) include genetic syndromes and high doses of radiation. Learn about ALL risk.
Symptoms of leukemia
Symptoms may vary depending on whether you have an acute or chronic type of leukemia.
Diagnosis of leukemia
Tests to diagnose leukemia, such as blood tests, are done when symptoms or routine tests suggest a problem.
Staging acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is not staged but described as untreated, in remission, relapsed or refractory. Learn about these descriptions of ALL.
Disease progression of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) progresses quickly and can develop wherever blood travels. Learn about where ALL can develop.
Prognosis and survival for acute lymphoblastic leukemia
Prognostic factors for acute lymphoblastic leukemia (ALL) include chromosome changes, classification and your age. Learn about prognostic factors for ALL.
Treatments for acute lymphoblastic leukemia
Treatments for acute lymphoblastic leukemia (ALL) can include chemotherapy, radiation therapy, targeted therapy and a stem cell transplant.
Supportive care for leukemia
Supportive care helps people with physical and emotional aspects of leukemia. Learn how to cope with long-term effects of leukemia.
Research in acute lymphoblastic leukemia (ALL)
Researchers and healthcare professionals take the knowledge gained from research studies and use it to develop better practices that will help prevent, find and treat acute lymphoblastic leukemia (ALL) as well as improve the quality of life of people with ALL.
Acute lymphoblastic leukemia statistics
Acute lymphoblastic leukemia (ALL) is the least common type of leukemia diagnosed in Canadian adults. Learn about statistics for this cancer.